Provided by Tiger Fintech (Singapore) Pte. Ltd.

Spero Therapeutics Inc.

2.71
+0.21008.40%
Volume:3.24M
Turnover:8.60M
Market Cap:151.52M
PE:-2.12
High:2.81
Open:2.55
Low:2.50
Close:2.50
Loading ...

Neumora Stock Hits Record Low on Depression Drug Study Failure

Zacks
·
03 Jan

MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN

Zacks
·
02 Jan

VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag

Zacks
·
02 Jan

Puma Biotechnology Stock Rises 24% in 3 Months: Here's Why

Zacks
·
27 Dec 2024

JNJ Inks Licensing Deal With Kaken for Eczema Candidate KP-723

Zacks
·
27 Dec 2024

BMY Gets EC Nod for Opdivo Plus Yervoy in First-Line Colorectal Cancer

Zacks
·
25 Dec 2024

AZN's Tagrisso Gets Approval in the EU for Expanded Use in NSCLC

Zacks
·
23 Dec 2024

Spero Therapeutics (SPRO) was downgraded to a Hold Rating at Evercore ISI

TIPRANKS
·
23 Dec 2024

VRTX Down as Non-Opioid Drug Shows Similar Pain Reduction as Placebo

Zacks
·
21 Dec 2024

Evercore ISI Downgrades Spero Therapeutics to In Line From Outperform, Price Target is $5

MT Newswires Live
·
20 Dec 2024

Spero Therapeutics Cut to In-Line From Outperform by Evercore ISI Group

Dow Jones
·
20 Dec 2024

MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host Disease

Zacks
·
20 Dec 2024

KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707

Zacks
·
20 Dec 2024

REGN's Eylea HD Shows Non-Inferiority to Eylea in Eye Disease Study

Zacks
·
18 Dec 2024

GILD's Trodelvy Gets Second Breakthrough Therapy Tag for Lung Cancer

Zacks
·
18 Dec 2024

EWTX Stock Rises on Upbeat Data From Rare Muscular Disorder Study

Zacks
·
17 Dec 2024

Merck Ends Development of Two Experimental Cancer Drugs

Zacks
·
17 Dec 2024

FDA Gives CRL to J&J's BLA for Subcutaneous Rybrevant in NSCLC

Zacks
·
17 Dec 2024

Spero Therapeutics (SPRO) Loses -9.32% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks
·
17 Dec 2024

CHMP Endorses Merck's Kidney Cancer Drug for Two Indications

Zacks
·
16 Dec 2024